The company reported preliminary results from the P-II (SAVANNAH) trial evaluating savolitinib + Tagrisso in 294 patients with EGFRm, LA, or metastatic NSCLC with MET overexpression & amplification at 80+ centers globally, incl. US, Canada, EU, South America & Asia
In P-II trial, EGFRm NSCLC patients with high levels of MET overexpression or amplification/ high levels of MET who were not treated with prior CT/ patients whose tumors did not show high levels of MET showed an ORR (49%/52%/9%); m-DoR (9.3/ 9.6/6.9mos.); m-PFS (7.1/7.2/2.8mos.); DCR (74%/75%/43%), respectively
The safety profile was consistent with the known profiles with no new safety signals, 45% experienced grade ≥3 AEs, Savolitinib was marketed under the brand name Orpathys in China
Ref: HUTCHMED | Image: HUTCHMED
